A potential role for psilocybin in the treatment of obsessive-compulsive disorder
Edward Jacobs
Publication record · Explore literaturePublic tracker catalogue and stored structured reference metadata. External references may have identifiers only. No live external citation lookup is performed.
References — this paper cites (135)
- Emotions and brain function are altered up to one month after a single high dose of psilocybin. 2020-02-10 · Expand citations
- Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. 2020-02-01 · Expand citations
- REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics. 2019-07-01 · Expand citations
- Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels 2019-06-01 · Expand citations
- Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. 2018-07-01 · Expand citations
- Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. 2018-02-01 · Expand citations
- Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. 2017-10-13 · Expand citations
- Long-term follow-up of psilocybin-facilitated smoking cessation. 2017-01-01 · Expand citations
- Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. 2017-01-01 · Expand citations
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. 2016-12-01 · Expand citations
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. 2016-12-01 · Expand citations
- Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. 2016-12-01 · Expand citations
- The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. 2016-01-01 · Expand citations
- Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. 2015-11-01 · Expand citations
- Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. 2015-10-15 · Expand citations
- Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. 2015-03-01 · Expand citations
- Psychedelics not linked to mental health problems or suicidal behavior: a population study. 2015-03-01 · Expand citations
- The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. 2015-01-01 · Expand citations
- Psilocybin and Obsessive Compulsive Disorder. 2014-01-01 · Expand citations
- Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. 2014-01-01 · Expand citations
- Broadband cortical desynchronization underlies the human psychedelic state. 2013-09-18 · Expand citations
- Psychedelics and mental health: a population study. 2013-01-01 · Expand citations
- Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. 2012-12-01 · Expand citations
- Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. 2012-02-07 · Expand citations
- Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. 2012-02-01 · Expand citations
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. 2011-12-01 · Expand citations
- Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. 2011-11-01 · Expand citations
- Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. 2011-11-01 · Expand citations
- Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. 2011-01-01 · Expand citations
- Effects of Psilocybe argentipes on marble-burying behavior in mice. 2009-08-01 · Expand citations
- Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents. 2008-01-01 · Expand citations
- Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. 2006-11-01 · Expand citations
- Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. 2004-03-01 · Expand citations
- Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. 1998-12-01 · Expand citations
- Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man 1997-06-01 · Expand citations
- Serotonin, psilocybin, and body dysmorphic disorder: a case report. 1996-04-01 · Expand citations
- Relief of obsessive-compulsive symptoms by LSD and psilocin 1987-09-01 · Expand citations
- Some biochemical studies on psilocybin and psilogin. 1963-04-01 · Expand citations
- [Elucidation of the structure and the synthesis of psilocybin]. 1958-11-15 · Expand citations
- OpenAlex W122113993
- OpenAlex W1784226620
- OpenAlex W1846321575
- OpenAlex W1964540177
- OpenAlex W1964698313
- OpenAlex W1965761294
- OpenAlex W1971459727
- OpenAlex W1978032191
- OpenAlex W1985748616
- OpenAlex W1995045083
- OpenAlex W1997161439
- OpenAlex W1997392319
- OpenAlex W1997452831
- OpenAlex W2001090794
- OpenAlex W2002443895
- OpenAlex W2005593798
- OpenAlex W2006587749
- OpenAlex W2012077435
- OpenAlex W2015011531
- OpenAlex W2029342476
- OpenAlex W2034593916
- OpenAlex W2036037381
- OpenAlex W2038928427
- OpenAlex W2042298460
- OpenAlex W2042307631
- OpenAlex W2043711264
- OpenAlex W2054754029
- OpenAlex W2055110970
- OpenAlex W2058064963
- OpenAlex W2063955964
- OpenAlex W2068751924
- OpenAlex W2071765462
- OpenAlex W2072467374
- OpenAlex W2076256173
- OpenAlex W2078740239
- OpenAlex W2080123927
- OpenAlex W2082535915
- OpenAlex W2089130066
- OpenAlex W2095643440
- OpenAlex W2098915263
- OpenAlex W2100861230
- OpenAlex W2101309614
- OpenAlex W2101582587
- OpenAlex W2104320372
- OpenAlex W2108292201
- OpenAlex W2111396411
- OpenAlex W2113099805
- OpenAlex W2120128279
- OpenAlex W2120918936
- OpenAlex W2129502536
- OpenAlex W2136435696
- OpenAlex W2140018908
- OpenAlex W2140172277
- OpenAlex W2159370497
- OpenAlex W2159990726
- OpenAlex W2166952073
- OpenAlex W2167273704
- OpenAlex W2171432760
- OpenAlex W2204342160
- OpenAlex W2319006982
- OpenAlex W2336389811
- OpenAlex W2341558148
- OpenAlex W2345258591
- OpenAlex W2551626080
- OpenAlex W2552814605
- OpenAlex W2593476122
- OpenAlex W2596797494
- OpenAlex W2609660019
- OpenAlex W2774876719
- OpenAlex W2780408016
- OpenAlex W2786472900
- OpenAlex W2788854095
- OpenAlex W2791704659
- OpenAlex W2792211781
- OpenAlex W2801279915
- OpenAlex W2804362986
- OpenAlex W2808301300
- OpenAlex W2889525702
- OpenAlex W2894846833
- OpenAlex W2895529315
- OpenAlex W2898717395
- OpenAlex W2987203272
- OpenAlex W2999812626
- OpenAlex W3108285700
- OpenAlex W3142791708
- OpenAlex W3217097423
- OpenAlex W4211150788
- OpenAlex W4211211437
- OpenAlex W4386315766
- OpenAlex W592732404
- OpenAlex W62922542
- OpenAlex W6649587555
- OpenAlex W6748386387
- OpenAlex W6755698176
- OpenAlex W6819150864
- OpenAlex W6821717516
Cited by — these papers cite this paper (2)
- Case Report: Repeated low doses of psilocybin reduce perceived symptom severity but fail to restore cognitive flexibility in a case of severe obsessive-compulsive disorder: an observational case study of identical twins 2026-04-21 · Expand citations
- PTSD Treatment: An Inquiry into the Promising Potential of Psilocybin 2024-07-24 · Expand citations